To:

From: UBS

Fax: UBS



UBS AG

Singapore Branch One Raffles Quay #50-01 North Tower Singapore 048583 Tel. +65 6495 8000

Group Risk Control

Fax

7 May 2018

To,

The BSE Limited Department of Corporate Services P.J. Towers, Dalal Street, Fort Mumbai 400 001	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E) Mumbai 400 051, India Attn: Listing Department		
Fortis Healthcare Limited Fortis Hospital Sector 62,Phase VIII, Mohali, Punjab – 160062, India			

Sub: Disclosure of interest pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011

Dear Sir/Madam,

Please find attached, a disclosure of shareholdings of 0.0003% in Fortis Healthcare Limited (ISIN: INE061F01013), pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011.Kindly contact Philip Alexander at +85 229716074 should you have any queries in relation to this matter.

Yours sincerely, UBS AG Group

Serene Peh

Group Risk Control

Philip Alexander

Group Risk Control

The information contained in this facsimile message is confidential information intended only for the individual or entity named herein. If the reader of this information is not the named recipient, you are hereby notified that any dissemination, distribution or copy of this facsimile is strictly prohibited. If you have received this facsimile in error, please immediately contact us by telephone and return the original message to us at the above address. Thank you.

From:UBS

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Fortis Healthcare Limited UBS PRINCIPAL CAPITAL ASIA LTD No BSE Limited and the National Stock Exchange of India Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer			
Whether the acquirer belongs to Promoter/Promoter group			
Name(s) of the Stock Exchange(s) where the shares of TC are Listed			
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/votin g capital of the TC (**)
Before the acquisition/ Sale under consideration, holding of :			
 a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others) c) Voting rights (VR) otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category) e) Total (a+b+c+d) 		5.44 % 5.44 %	5.44 % 5.44 %
		7.44 70	5.44 70
a) Shares carrying voting rights acquired/sold b) VRs acquired /sold otherwise than by shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold d) Shares encumbered / invoked/released by the	a) 28,231,975 b) NIL c) NIL d) NIL	5.44 %	5.44%
acquirer e) Total (a+b+c+d)	e) 28,231,975	5.44%	5.44%

From:UBS

After the a cquisition /sale, holding of:				
 a) Shares carrying voting rights b) Shares encumbered with the acquirer c) VRs otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each 	a) 1,800 b) NIL c) NIL d) NIL	0.0003%	0.0003%	
category) after acquisition e) Total (a+b+c+d)	ie) 1,800	0.0003%	0.0003%	
Mode of acquisition / sale (e.g. open market / off- market / public issue / rights issue / preferential allotment / inter-se transfer etc.)	Open Market		<u> </u>	
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	3-May-2018			
Equity share capital / total voting capital of the TC before the said acquisition / sale	518,657,231(as per BSE)			
Equity share capital/ total voting capita of the TC after the said acquisition / sale	518,657,231(as per BSE)			
Total diluted share/voting capital of the TC after the said acquisition	518,657,231(as per BSE)			

- (*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
- (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer / seller / Authorized Signatory

Serene Peh

Group Risk Control

Philip Alexander **Group Risk Control**

Place: UBS AG, Singapore Branch

Date: May 07,2018
